Clinical Trial Update: A Study of RO5503781 as a Single Agent or in Combination With Cytarabine in Participants With Acute Myelogenous Leukemia [Phase 1]

View source ↗

Summary

Phase 1 study of RO5503781 as a single agent or in combination with cytarabine in participants with acute myeloid leukemia has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• CYTARABINE (CYTARABINE)
• RO5503781

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Myelogenous Leukemia, Acute | Phase 1 | Status: COMPLETED